These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 28541488

  • 1. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
    Schurich A, Raine C, Morris V, Ciurtin C.
    Rheumatology (Oxford); 2018 Feb 01; 57(2):246-254. PubMed ID: 28541488
    [Abstract] [Full Text] [Related]

  • 2. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M, Alwawi E, Gordon KB.
    Semin Cutan Med Surg; 2010 Mar 01; 29(1):48-52. PubMed ID: 20430307
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
    Johnsson HJ, McInnes IB.
    Clin Exp Rheumatol; 2015 Mar 01; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
    [Abstract] [Full Text] [Related]

  • 6. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.
    Martin R.
    Lancet Neurol; 2008 Sep 01; 7(9):765-6. PubMed ID: 18702995
    [No Abstract] [Full Text] [Related]

  • 7. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.
    Ann N Y Acad Sci; 2011 Mar 01; 1222():30-9. PubMed ID: 21434940
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Briakinumab for the treatment of plaque psoriasis.
    Traczewski P, Rudnicka L.
    BioDrugs; 2012 Feb 01; 26(1):9-20. PubMed ID: 22077474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
    Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ.
    Nat Med; 2015 Jul 01; 21(7):719-29. PubMed ID: 26121196
    [Abstract] [Full Text] [Related]

  • 12. IL-12-and IL-23 in health and disease.
    Croxford AL, Kulig P, Becher B.
    Cytokine Growth Factor Rev; 2014 Aug 01; 25(4):415-21. PubMed ID: 25130295
    [Abstract] [Full Text] [Related]

  • 13. Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
    Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A.
    Clin Pharmacol Ther; 2018 Jan 01; 103(1):88-101. PubMed ID: 28960267
    [Abstract] [Full Text] [Related]

  • 14. Briakinumab.
    Lima XT, Abuabara K, Kimball AB, Lima HC.
    Expert Opin Biol Ther; 2009 Aug 01; 9(8):1107-13. PubMed ID: 19569977
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
    Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR.
    Dermatol Online J; 2012 Oct 15; 18(10):1. PubMed ID: 23122008
    [Abstract] [Full Text] [Related]

  • 16. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
    Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA.
    MAbs; 2011 Oct 15; 3(6):535-45. PubMed ID: 22123062
    [Abstract] [Full Text] [Related]

  • 17. Ustekinumab poised to enter the psoriasis market.
    Schmidt C.
    Nat Biotechnol; 2008 Dec 15; 26(12):1317-8. PubMed ID: 19060851
    [No Abstract] [Full Text] [Related]

  • 18. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A, Laiz A, Puig L.
    Expert Opin Drug Saf; 2017 Jun 15; 16(6):733-742. PubMed ID: 28441904
    [Abstract] [Full Text] [Related]

  • 19. The role of IL 23 in the treatment of psoriasis.
    Puig L.
    Expert Rev Clin Immunol; 2017 Jun 15; 13(6):525-534. PubMed ID: 28165883
    [Abstract] [Full Text] [Related]

  • 20. Novel biologic therapies in development targeting IL-12/IL-23.
    van de Kerkhof PC.
    J Eur Acad Dermatol Venereol; 2010 Oct 15; 24 Suppl 6():5-9. PubMed ID: 20831703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.